Biolase, Inc. (NASDAQ:BIOL) major shareholder Larry N. Feinberg purchased 12,545,615 shares of the stock in a transaction that occurred on Tuesday, December 5th. The stock was acquired at an average cost of $0.43 per share, with a total value of $5,394,614.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of Biolase, Inc. (NASDAQ:BIOL) traded up $0.03 on Wednesday, reaching $0.42. The company had a trading volume of 1,446,100 shares, compared to its average volume of 157,019. Biolase, Inc. has a 52-week low of $0.28 and a 52-week high of $1.90.

Separately, ValuEngine raised Biolase from a “sell” rating to a “hold” rating in a report on Monday, October 2nd.

ILLEGAL ACTIVITY NOTICE: “Biolase, Inc. (BIOL) Major Shareholder Larry N. Feinberg Purchases 12,545,615 Shares” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at

Biolase Company Profile

BIOLASE, Inc (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers.

Receive News & Ratings for Biolase Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biolase Inc. and related companies with's FREE daily email newsletter.